On February 18, Cerus Endovascular announced that it won CE Mark approval for its Contour neurovascular system, which is used to treat intracranial aneurysms.

This new alternative embolisation device will likely enter the market in Q2 2020 and will compete against MicroVention’s WEB aneurysm embolisation system.

GlobalData estimates that the global intrasaccular device market will grow at a Compound Annual Growth Rate (CAGR) of 6% over the next 10 years, with North America and Europe being the fastest growing regions. The complexity of wide-neck bifurcated aneurysms remains a challenge in treatment, and intrasaccular devices aim to overcome that challenge. MicroVention’s WEB device is the first and currently only intrasaccular device on the market, and was designed to fill the aneurysm with less metal than traditional coils and to promote clotting. Now that it has gained CE Mark approval, the Contour stent will attempt to overcome the same treatment challenges with a different design than the WEB, as the Contour device mimics an umbrella that is opened inside the aneurysm.

The Contour device attempts to address several challenges with treating wide-neck bifurcated aneurysms, as well as challenges with the WEB itself. The umbrella design allows for flow diversion at the neck of the aneurysm as well as within it. Without actually filling the aneurysm, this keeps metal away from the potential rupture zone and simplifies the sizing approach. Correct sizing to fill the aneurysm is a major issue with the WEB device.

Both the WEB and Contour devices boast the minimised need for dual antiplatelet therapy, which is a large driver the forecast increased adoption rate, particularly in the endovascular treatment of ruptured aneurysms. GlobalData expects that the global intrasaccular device market and the adoption of both devices will grow rapidly over the next 10 years. However, the next five years will be critical in determining whether the Contour device will be successful, whether or not its innovative design will prove to have better outcomes than the WEB, and whether these superior results are enough to take a portion of the market share from a manufacturer with significantly larger distribution networks, product portfolios, and resources.